OTIC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (12 Apr 2023 @ 03:58):

Stats
今日成交量	1.94M
平均成交量	876 957
市值	582 482
EPS	$0 ( 2023-11-08 )
Last Dividend	$0.110 ( 2023-04-11 )
Next Dividend	$0 ( N/A )
P/E	-0.142
ATR14	$0.00500 (58.82%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-15	Hogan H Michael Iii	Buy	0
2022-12-30	Weber David Allen	Sell	91 636	Common Stock
2022-12-28	Cayer Paul E	Sell	40 054	Common Stock
2022-11-28	Capps Vickie L	Sell	42 242	Common Stock
2022-06-21	Schroeder Theodore R	Buy	27 500	Stock Option (right to buy)

INSIDER POWER
-37.51
Last 98 transactions
Buy: 7 968 332 \| Sell: 3 029 863

音量相关性

長: 0.68 (moderate)

短: -0.97 (very strong negative)

Signal:(8.549) Possible Trading Opportunity Present (swing)

Otonomy Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Otonomy Inc 相关性 - 货币/商品

0.12
( neutral )

0.06
( neutral )

0.00
( neutral )

0.14
( neutral )

-0.52
( weak negative )

-0.22
( neutral )

Otonomy Inc 财务报表

Annual	2021
营收:	$125 000
毛利润:	$-245 000 (-196.00 %)
EPS:	$-0.810

FY	2021
营收:	$125 000
毛利润:	$-245 000 (-196.00 %)
EPS:	$-0.810

FY	2020
营收:	$273 000
毛利润:	$-915 000 (-335.16 %)
EPS:	$-1.100

FY	2019
营收:	$600 000
毛利润:	$-312 000 (-52.00 %)
EPS:	$-1.450

Financial Reports:

No articles found.

Otonomy Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.110 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Otonomy Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.110	2023-04-11
Last Dividend	$0.110	2023-04-11
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.110	--
Avg. Dividend % Per Year	39.17%	--
Score	4.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-06)

$0.220 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$0.110	117.50%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-402.60	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.526	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	0.0949	1.500	-0.0565	-0.0848	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	6.52	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	6.28	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.166	-1.500	7.24	-10.00	[0 - 0.6]
interestCoverageTTM	-31.04	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.669	2.00	-0.223	-0.446	[0 - 30]
freeCashFlowPerShareTTM	-0.673	2.00	-0.337	-0.673	[0 - 20]
debtEquityRatioTTM	-0.0285	-1.500	-0.114	0.171	[0 - 2.5]
grossProfitMarginTTM	-1.960	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-397.00	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-2.68	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00131	0.800	-3.32	-2.66	[0.5 - 2]
Total Score				-3.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.0107	1.000	-0.102	0	[1 - 100]
returnOnEquityTTM	0.0949	2.50	-0.0363	-0.0848	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.673	2.00	-0.224	-0.673	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.669	2.00	-0.223	-0.446	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-339.34	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-1.609

Otonomy Inc

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.